Canopy Growth announces clinical trial approval for the use of cannabis to treat anxiety in certain animals

TORONTO and SMITHS FALLS, ON, Aug. 8, 2018 /CNW/ – Canopy Growth Corporation (TSX: WEED) (NYSE: CGC) (“Canopy Growth” or the “Company”) and its wholly owned subsidiary, Canopy Health Innovations Inc. (“Canopy Health” or “CHI”) is pleased to announce that approval has been received from the Veterinary Drug Directorate of Health Canada to research the effectiveness of cannabidiol (“CBD”) to treat anxiety in certain animals. The research will be conducted by Canopy Animal Health (“CAH”), a division of Canopy Health which focuses on developing cannabis-based healthcare products for companion animals.

Canopy Growth Announces Clinical Trial Approval for the Use of Cannabis to Treat Certain Animals (CNW Group/Canopy Growth Corporation)

The approval comes in the form of a No Objection Letter for the use of a proprietary CBD enriched oil

... read more at: